| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.39▲ | 1.38▲ | 1.38▲ | 1.36▲ | 1.42▼ |
| MA10 | 1.39▲ | 1.37▲ | 1.37▲ | 1.34▲ | 1.69▼ |
| MA20 | 1.38▲ | 1.37▲ | 1.35▲ | 1.42▼ | 1.74▼ |
| MA50 | 1.37▲ | 1.33▲ | 1.32▲ | 1.74▼ | 2.48▼ |
| MA100 | 1.37▲ | 1.32▲ | 1.36▲ | 1.76▼ | 6.57▼ |
| MA200 | 1.34▲ | 1.37▲ | 1.56▼ | 2.12▼ | 10.00▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.001▲ | 0.003▲ | 0.017▲ | 0.038▲ |
| RSI | 67.106▲ | 65.386▲ | 62.818▲ | 43.442▼ | 36.615▼ |
| STOCH | 57.778 | 80.455▲ | 69.242 | 52.662 | 7.422▼ |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -37.997 | -89.856▼ |
| CCI | 117.230▲ | 127.837▲ | 146.432▲ | 32.362 | -100.815▼ |
|
Wednesday, November 12, 2025 02:12 AM
The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A ...
|
|
Monday, November 10, 2025 04:00 AM
About Biomea Fusion Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies for diabetes and obesity; icovamenib, a selective menin inhibitor for diabetes ...
|
|
Tuesday, November 04, 2025 01:18 PM
Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/11/25 | 1.37 | 1.405 | 1.3335 | 1.40 | 1,026,373 |
| 10/11/25 | 1.40 | 1.40 | 1.33 | 1.37 | 904,432 |
| 07/11/25 | 1.27 | 1.38 | 1.24 | 1.37 | 1,172,386 |
| 06/11/25 | 1.33 | 1.34 | 1.28 | 1.30 | 553,908 |
| 05/11/25 | 1.25 | 1.355 | 1.2205 | 1.34 | 909,499 |
| 04/11/25 | 1.29 | 1.32 | 1.24 | 1.26 | 1,219,201 |
| 03/11/25 | 1.38 | 1.395 | 1.27 | 1.32 | 1,326,181 |
| 31/10/25 | 1.36 | 1.38 | 1.31 | 1.36 | 818,239 |
| 30/10/25 | 1.36 | 1.38 | 1.31 | 1.33 | 1,208,382 |
| 29/10/25 | 1.41 | 1.42 | 1.34 | 1.37 | 1,229,508 |
|
|
||||
|
|
||||
|
|